Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 28,766

Document Document Title
WO/2014/169214A1
This invention provides processes to convert biomass, including wood and agricultural residues, to levulinic acid and co-products. Some variations treat feedstock with steam and/or hot water to produce an extract liquor containing hemice...  
WO/2014/167108A1
The invention relates to tetrahydrofuran derivatives of general formula (I), wherein X stands for ⋆-(C=O)-O-, ⋆-(CH2)n-O-, or ⋆-(CH2)n-O-(C=O)-, wherein * represents the point of bonding to the tetrahydrofuran ring and n has the va...  
WO/2014/163500A1
2,5-Furandicarboxylic acid and methyl acetate are prepared in a continuous process, comprising -introducing a 5-methoxymethylfurfural-containing feedstock, an oxygen-containing gas, an oxidation catalyst and an acetic acid-containing sol...  
WO/2014/165827A1
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demye...  
WO/2014/159226A1
A method is disclosed for making an unsaturated glycitan ester by reacting intramolecular condensates of glycitols having four or more carbons with a metathesis-derived unsaturated fatty acid in the presence of an alkaline catalyst and u...  
WO/2014/160649A1
This invention pertains generally to antibacterial organic compounds of Formula I as described herein, and pharmaceutical compositions containing such compounds. In certain aspects, the invention pertains to treating infections caused by...  
WO/2014/157018A1
A novel organic compound represented by a formula (G1) that forms an exciplex emitting light with high efficiency is provided. By the use of the organic compound and an organic compound with an electron-transport property, an exciplex th...  
WO/2014/157021A1
The compound expressed by formula (1) [in the formula, X represents a hydrogen atom, a fluorine atom, chlorine atom, or bromine atom, and Y represents a hydrogen atom, a fluorine atom, chlorine atom, or bromine atom] that is useful as a ...  
WO/2014/159559A1
The disclosure provides compounds of formula I or II, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infe...  
WO/2014/160940A2
Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III,...  
WO/2014/155291A1
The invention provides processes for the manufacture of a compound of formula (IA ). The invention further provides improved methods for the conversion of the compound of formula (I A ) into pregabalin.  
WO/2014/159741A1
The present disclosure provides methods for purifying a 5-(halomethyl)furfural composition, including 5-(chloromethyl)furfural, at operating conditions that decrease or minimize the decomposition or degradation of 5-(chloromethyl)furfura...  
WO/2014/157238A1
The present invention addresses the problem of providing a photoelectric conversion material that excels in heat resistance and vapor-deposition stability, a photoelectric conversion element using the photoelectric conversion material, a...  
WO/2014/159738A2
Provided are solid forms of 5-(halomethyl)furfural, including a crystalline form of 5- (chloromethyl)furfural. Provided are also methods for preparing solid forms of 5- (halomethyl)furfural by crystallization using certain solvents.  
WO/2014/158838A1
A process is described for converting HMF to FDCA, comprising dissolving a quantity of HMF in water to form an aqueous solution including HMF, combining the aqueous solution including HMF with an oxygen source in the presence of a homoge...  
WO/2014/157574A1
Provided are: a new material useful as an organic electroluminescent element material, namely a condensed fluoranthene compound having a heteroatom on an indeno[3,2-b] fluoranthene backbone; a material for an organic electroluminescent e...  
WO/2014/159802A1
The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulator...  
WO/2014/154676A1
Disclosed is a method for the isomerisation of glucose by reduction to sorbitol and subsequent oxidation into fructose, in which the redox cofactors NAD+/NADH and NADP+/NADPH are regenerated in a one-pot reaction, wherein one of the two ...  
WO/2014/147271A1
The invention relates to a method for the synthesis of enantiomerically pure cyclic lactones, such as (S)-y-hydroxymethyl-α,β-butenolide and (S)-4-hydroxymethyl-y-butyrolactone and the derivatives thereof, characterised in that it comp...  
WO/2014/146604A1
Provided is a fused ring compound having GPR40 receptor function regulating action, and preparation method and pharmaceutical compositions thereof, and the use thereof in drugs for the treatment and/or prevention of diseases associated w...  
WO/2014/148053A1
This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a...  
WO/2014/150384A1
A method for the manufacture of 1,8-octanedioic acid comprises: reacting gamma-valerolactone with an alcohol in the presence of an acid or a base catalyst to provide an alkyl pentenoate, converting the alkyl pentenoate in the presence of...  
WO/2014/148591A1
The present invention provides a method for efficiently producing an optically active 1, 2-diol compound from an olefin. The production method for the optically active 1, 2-diol compound is characterized by including: a step in which an ...  
WO/2014/139080A1
This invention relates to a novel method for the preparation of 3-oxotetrahydrofuran comprising oxidating 3-hydroxy-tetrahydrofuran in the presence of a catalytic amount of TEMPO with trichloroisocyanuric acid.  
WO/2014/140398A1
The invention concerns a method of obtaining organic molecules which involves at least the following steps: (a) a first step of selective oxidative esterification of the HMF formyl group with methanol in the presence of at least a metal ...  
WO/2014/142289A1
This method for manufacturing a lignin degradation product has: (1) a degradation step for degrading, under the conditions listed below, a raw material containing a plant-type biomass in a solvent that is a mixed solvent of water and a f...  
WO/2014/140017A1
This invention relates to a novel method for the preparationof 3-oxotetrahydrofurancomprising oxidating 3-hydroxy-tetrahydrofuran in the presence of a catalytic amount of TEMPO with trichloroisocyanuric acid.  
WO/2014/142219A1
[Problem] To provide a compound useful as a drug for preventing and/or treating kidney disease. [Solution] The inventors studied compounds having trypsin-inhibiting activity, confirmed that guanidinobenzoic acid ester compounds have tryp...  
WO/2014/141725A1
An anthracene derivative represented by formula (1). In formula (1), L1 is selected from a single bond and a linking group, the linking group being selected from groups formed by linking 2 to 4 of the following: bivalent arylene groups, ...  
WO/2014/139963A1
The invention is directed to a cosmetic composition and the precursor thereof. The composition has solid agent and liquid agent, both of which are cosmetic benefit ingredients. The solubility of solid agents in liquid agents in the inven...  
WO/2014/138823A1
The present disclosure relates to compounds of formula I in the treatment and/or prevention of a Gram-negative bacterial infection in a multicellular organism. The disclosure also relates to a pharmaceutical composition comprising said c...  
WO/2014/137301A1
It has been aimed in this invention to synthesize novel compounds having an original diflunisal hydrazide-hydrazone and 4-thiazolidone structures which may have the effect to inhibit DNA gyrase enzymes and which may be anticancer and HCV...  
WO/2014/135776A1
The invention relates to abexinostate tosylate of formula (II): and the crystalline form I thereof, characterized by the powder diffraction pattern X thereof, the Raman spectrum thereof, and the solid state 13C CP/MAS NMR spectrum thereo...  
WO/2014/135095A1
Provided are compounds of formula (I) and methods of controlling insects, acarines, nematodes or molluscs, which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acarici...  
WO/2014/132178A2
The present invention concerns the use of a furfural derivative of formula (I) in which R represents (i) a -CH=CR'1-COR1 group, a group (ii), a group (iii), a group (iv) or a -CHO group and R' represents a hydrogen atom or a (C1-C4)alkyl...  
WO/2014/133416A3
The present invention relates to novel chemical compounds of general formula 1 which are intermediate products of the synthesis of androgen receptor inhibitors that are of interest as anticancer preparations. The subject matter of the in...  
WO/2014/133361A1
The present invention relates to: a compound selected from the group consisting of a tricyclic compound having the structure of formula I, a pharmaceutically acceptable salt, an isomer, a solvate and a precursor thereof; and a use thereo...  
WO/2014/132975A1
In this method, a diastereomeric mixture containing a (2R)-2-fluoro-2-C-methyl-D-ribono-γ-lactone precursor is deprotected under acidic conditions; subsequently, by lactonizing the same, a diastereomeric mixture of dihydroxylactone is o...  
WO/2014/131825A1
The present invention relates to a multilayer tablet formulation comprising a combination of quetiapine or a pharmaceutically acceptable salt thereof and escitalopram or a pharmaceutically acceptable salt thereof.  
WO/2014/132178A3
The present invention concerns the use of a furfural derivative of formula (I) in which R represents (i) a -CH=CR'1-COR1 group, a group (ii), a group (iii), a group (iv) or a -CHO group and R' represents a hydrogen atom or a (C1-C4)alkyl...  
WO/2014/129846A1
The present invention relates to organic electroluminescent compounds of formula 1 (see below) wherein X, A, B, C and R4, R5, R6, R7, a, b, c. d. e, l, m, and n are as defined in the description. The invention also relates to organic ele...  
WO/2014/128723A3
The invention disclosed herein relates to novel Peribysin E analogues of general formula-I. Further the invention provides simple, economical and short synthesis of Peribysin E and its analogues of Formula I, in good yield and purity lea...  
WO/2014/129874A1
The present invention relates to: a novel α,β-unsaturated amide compound; a method for preparing a composition for preventing or treating obesity, comprising the steps of selecting a compound showing an obesity prevention or treatment ...  
WO/2014/129612A1
The present invention provides a process for producing a compound of the formula (1) wherein X represents a hydrogen atom, etc., and Y represents a hydrogen atom, etc., which comprises step 1 of reacting a compound of the formula (2) and...  
WO/2014/128723A2
The invention disclosed herein relates to novel Peribysin E analogues of general formula-I. Further the invention provides simple, economical and short synthesis of Peribysin E and its analogues of Formula I, in good yield and purity lea...  
WO/2014/127053A3
Processes and methods for making ultra-pure (> 99.50% by weight), biobased crotonic acid, gamma-butyro lactone, acrylic acid and delta-valerolactone from renewable carbon resources are described herein.  
WO/2014/125145A1
The invention relates to a novel method for modifying hydroxylated cyclic amino acids, especially 4-hydroxyproline, which is a commercial, relatively cheap, natural amino acid, in order to provide other amino acids of high optical purity...  
WO/2014/124552A1
The present invention relates to N-substituted amino butyrolactone derivatives and uses thereof. In particular, the present invention relates to compounds of formula I or pharmaceutically acceptable salts, solvates, esters, prodrugs, iso...  
WO/2014/125075A1
The present invention relates to a antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which comprise carbon, sulphur, nitrog...  
WO/2014/126068A1
The present invention provides a catalyst precursor which contains ruthenium that has a first ligand, which is a chiral cyclic diene ligand, and a second ligand.  

Matches 151 - 200 out of 28,766